转移性乳腺癌患者接受CDK4-6抑制剂治疗的修饰性缓解症指数和存活率
Onur Baş1, Mert Tokatlı2, Mehmet Şavklıyıldız2
1Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Expert review of anticancer therapy
|February 24, 2025
概括
修改后缓解症指数 (mCXI) 与转移性乳腺癌患者的更好的生存率有关,这些患者接受了循环林依赖激酶 (CDK) 4/6抑制剂. 这一发现有助于预测接受这些向治疗的患者的结果.
科学领域:
- 在瘤学瘤学.
- 医学统计 医学统计
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性乳腺癌 (mBC) 存在重大生存挑战.
- 循环素依赖性激酶 (CDK) 4/6 抑制剂在mBC中改善了结果.
- 确定预后因素对于优化治疗策略至关重要.
研究的目的:
- 调查修改后缓解症指数 (mCXI) 与生存结果之间的相关性.
- 为了评估mCXI的预后价值,在接受CDK 4/6抑制剂治疗的mBC患者.
主要方法:
- 对240名接受Palbociclib或Ribociclib治疗的mBC患者的回顾性分析.
- 根据ROC分析的整体存活期 (OS) 将患者分为mCXI-Low和mCXI-High组.
- 多变量分析以评估mCXI与无进展生存 (PFS) 和OS的关联.
主要成果:
- 修改后缓解症指数 (mCXI) 与无进展生存期 (PFS) [HR:1.50,p=0.02]和整体生存期 (OS) [HR:3.22,p<0.001]显著相关.
- 接收器操作特征 (ROC) 分析发现mCXI的切断值为93.5,用于预测OS (AUC:0.654,p<0.001).
- 该研究包括240名患者,主要是女性 (98.3%),平均年龄为57岁.
结论:
- 修改后缓解症指数 (mCXI) 是接受CDK 4/6抑制剂的转移性乳腺癌患者整体生存的显著独立预后因素.
- mCXI可以帮助风险分层,并可能指导这种患者群体的治疗决策.
更多相关视频
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
876
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
相关概念视频
01:21Cancer Survival Analysis
320
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
320
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K